PMID- 36260549
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221022
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 10
DP  - 2022
TI  - Examining the relationship between metformin dose and cancer survival: A 
      SEER-Medicare analysis.
PG  - e0275681
LID - 10.1371/journal.pone.0275681 [doi]
LID - e0275681
AB  - Cancer is a major health problem in the U.S and type 2 diabetes mellitus (T2DM) 
      is known to increase the risk for the development of many cancers. Metformin, a 
      first-line therapy for treating T2DM, is increasingly being used for its 
      anticancer effects; however, the literature is limited on the effect of metformin 
      dose on overall survival in patients with stage IV cancer. Overall survival was 
      defined as the time interval from the date of diagnosis to the last known 
      follow-up or death from any cause. Subjects who were alive on December 31, 2016 
      were censored. In this cohort study we examined the relationship between 
      metformin dose and overall survival in persons with both T2DM and stage IV lung, 
      breast, colorectal, prostate, or pancreas cancers. We used a retrospective study 
      design with Cox proportional hazards regression analysis of the 2007-2016 of the 
      Surveillance Epidemiology and End Results-Medicare (SEER) dataset. Of the 7,725 
      patients, 2,981(38.5%) had been prescribed metformin. Patients who used metformin 
      had significantly better overall survival in both unadjusted (Unadjusted HR, 
      0.73; 95% CI, 0.69-0.76; p < 0.001) and adjusted models (adjusted HR, 0.77; 95% 
      CI, 0.73-0.81; p < 0.001). The overall survival between patients who took 
      metformin with average daily dose >/= 1000mg or < 1000mg were not statistically 
      significant (aHR, 1.00; 95% CI, 0.93-1.08; p = 0.90). Metformin use regardless of 
      dose is associated with increased overall survival in older adults with stage IV 
      cancer.
FAU - Scarton, Lisa
AU  - Scarton L
AUID- ORCID: 0000-0003-1255-0811
AD  - Department of Family, Community, and Health Systems Science, College of Nursing, 
      University of Florida, Gainesville, Florida, United States of America.
FAU - Jo, Ara
AU  - Jo A
AD  - Department of Health Services Research, Management and Policy, College of Public 
      Health and Health Professions, University of Florida, Gainesville, Florida, 
      United States of America.
FAU - Xie, Zhigang
AU  - Xie Z
AD  - Department of Public Health, University of North Florida, Jacksonville, Florida, 
      United States of America.
FAU - O'Neal, LaToya J
AU  - O'Neal LJ
AD  - Institute of Food and Agricultural Sciences, University of Florida, Gainesville, 
      Florida, United States of America.
FAU - Munoz Pena, Juan M
AU  - Munoz Pena JM
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      College of Medicine, University of Florida, Gainesville, Florida, United States 
      of America.
FAU - George, Thomas J
AU  - George TJ
AD  - Division of Hematology and Oncology, College of Medicine, University of Florida, 
      Gainesville, Florida, United States of America.
FAU - Bian, Jiang
AU  - Bian J
AD  - Health Outcomes and Biomedical Informatics, College of Medicine, University of 
      Florida, Gainesville, Florida, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20221019
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 9100L32L2N (Metformin)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Male
MH  - Humans
MH  - Aged
MH  - United States/epidemiology
MH  - *Metformin/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Hypoglycemic Agents/therapeutic use
MH  - Cohort Studies
MH  - Retrospective Studies
MH  - Medicare
MH  - *Pancreatic Neoplasms/drug therapy
PMC - PMC9581409
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/10/20 06:00
MHDA- 2022/10/22 06:00
PMCR- 2022/10/19
CRDT- 2022/10/19 13:32
PHST- 2022/02/18 00:00 [received]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/10/19 13:32 [entrez]
PHST- 2022/10/20 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/10/19 00:00 [pmc-release]
AID - PONE-D-22-05039 [pii]
AID - 10.1371/journal.pone.0275681 [doi]
PST - epublish
SO  - PLoS One. 2022 Oct 19;17(10):e0275681. doi: 10.1371/journal.pone.0275681. 
      eCollection 2022.